Literature DB >> 16484590

Role of transforming growth factor-beta in hematologic malignancies.

Mei Dong1, Gerard C Blobe.   

Abstract

The transforming growth factor-beta (TGF-beta) signaling pathway is an essential regulator of cellular processes, including proliferation, differentiation, migration, and cell survival. During hematopoiesis, the TGF-beta signaling pathway is a potent negative regulator of proliferation while stimulating differentiation and apoptosis when appropriate. In hematologic malignancies, including leukemias, myeloproliferative disorders, lymphomas, and multiple myeloma, resistance to these homeostatic effects of TGF-beta develops. Mechanisms for this resistance include mutation or deletion of members of the TGF-beta signaling pathway and disruption of the pathway by oncoproteins. These alterations define a tumor suppressor role for the TGF-beta pathway in human hematologic malignancies. On the other hand, elevated levels of TGF-beta can promote myelofibrosis and the pathogenesis of some hematologic malignancies through their effects on the stroma and immune system. Advances in the TGF-beta signaling field should enable targeting of the TGF-beta signaling pathway for the treatment of hematologic malignancies.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16484590      PMCID： PMC1895802          DOI： 10.1182/blood-2005-10-4169

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  90 in total

Review 1.  Decitabine in chronic leukemias.

Authors:  Jean-Pierre J Issa; John C Byrd
Journal:  Semin Hematol       Date:  2005-07       Impact factor: 3.851

Review 2.  Role of transforming growth factor Beta in human cancer.

Authors:  Rebecca L Elliott; Gerard C Blobe
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

3.  Human T-cell leukemia virus type I oncoprotein Tax represses Smad-dependent transforming growth factor beta signaling through interaction with CREB-binding protein/p300.

Authors:  N Mori; M Morishita; T Tsukazaki; C Z Giam; A Kumatori; Y Tanaka; N Yamamoto
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

4.  Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.

Authors:  Toshiaki Hayashi; Teru Hideshima; Aaron N Nguyen; Olivier Munoz; Klaus Podar; Makoto Hamasaki; Kenji Ishitsuka; Hiroshi Yasui; Paul Richardson; Sarvajit Chakravarty; Alison Murphy; Dharminder Chauhan; Linda S Higgins; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2004-11-15       Impact factor: 12.531

5.  A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma.

Authors:  W P Schiemann; W M Pfeifer; E Levi; M E Kadin; H F Lodish
Journal:  Blood       Date:  1999-10-15       Impact factor: 22.113

Review 6.  Development of TGF-beta signalling inhibitors for cancer therapy.

Authors:  Jonathan M Yingling; Kerry L Blanchard; J Scott Sawyer
Journal:  Nat Rev Drug Discov       Date:  2004-12       Impact factor: 84.694

7.  TGFbeta-mediated activation of Smad1 in B-cell non-Hodgkin's lymphoma and effect on cell proliferation.

Authors:  O Munoz; F Fend; R de Beaumont; H Husson; A Astier; A S Freedman
Journal:  Leukemia       Date:  2004-12       Impact factor: 11.528

8.  A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis.

Authors:  Alessandro M Vannucchi; Lucia Bianchi; Francesco Paoletti; Alessandro Pancrazzi; Eugenio Torre; Mitsuo Nishikawa; Maria Zingariello; Angela Di Baldassarre; Rosa Alba Rana; Rodolfo Lorenzini; Elena Alfani; Giovanni Migliaccio; Anna Rita Migliaccio
Journal:  Blood       Date:  2005-01-21       Impact factor: 22.113

9.  TGF-{beta}1 activates two distinct type I receptors in neurons: implications for neuronal NF-{kappa}B signaling.

Authors:  Hans-Georg König; Donat Kögel; Abdelhaq Rami; Jochen H M Prehn
Journal:  J Cell Biol       Date:  2005-03-21       Impact factor: 10.539

Review 10.  RNA interference: from gene silencing to gene-specific therapeutics.

Authors:  Ray K M Leung; Paul A Whittaker
Journal:  Pharmacol Ther       Date:  2005-08       Impact factor: 12.310
View more
  76 in total

1.  Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis.

Authors:  Catharina Wenk; Anne-Kathrin Garz; Sonja Grath; Christina Huberle; Denis Witham; Marie Weickert; Roberto Malinverni; Julia Niggemeyer; Michèle Kyncl; Judith Hecker; Charlotta Pagel; Christopher B Mulholland; Catharina Müller-Thomas; Heinrich Leonhardt; Florian Bassermann; Robert A J Oostendorp; Klaus H Metzeler; Marcus Buschbeck; Katharina S Götze
Journal:  Blood Adv       Date:  2018-12-11

2.  Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase.

Authors:  Mandy Brecqueville; Jérôme Rey; Raynier Devillier; Arnaud Guille; Rémi Gillet; José Adélaide; Véronique Gelsi-Boyer; Christine Arnoulet; Max Chaffanet; Marie-Joelle Mozziconacci; Norbert Vey; Daniel Birnbaum; Anne Murati
Journal:  Haematologica       Date:  2013-08-30       Impact factor: 9.941

3.  Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.

Authors:  Thomas Clozel; ShaoNing Yang; Rebecca L Elstrom; Wayne Tam; Peter Martin; Matthias Kormaksson; Samprit Banerjee; Aparna Vasanthakumar; Biljana Culjkovic; David W Scott; Sarah Wyman; Micheal Leser; Rita Shaknovich; Amy Chadburn; Fabrizio Tabbo; Lucy A Godley; Randy D Gascoyne; Katherine L Borden; Giorgio Inghirami; John P Leonard; Ari Melnick; Leandro Cerchietti
Journal:  Cancer Discov       Date:  2013-08-16       Impact factor: 39.397

Review 4.  Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β.

Authors:  Archana Agarwal; Kerry Morrone; Matthias Bartenstein; Zhizhuang Joe Zhao; Amit Verma; Swati Goel
Journal:  Stem Cell Investig       Date:  2016-02-26

5.  Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro.

Authors:  Muna Iraqi; Jose Perdomo; Feng Yan; Philip Y-I Choi; Beng H Chong
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

6.  Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma.

Authors:  Stavroula Baritaki; Sara Huerta-Yepez; Ma da Lourdas Cabrava-Haimandez; Marialuisa Sensi; Silvana Canevari; Massimo Libra; Manuel Penichet; Haiming Chen; James R Berenson; Benjamin Bonavida
Journal:  For Immunopathol Dis Therap       Date:  2011-04-01

7.  Stromal cell-derived factor-1α and transforming growth factor-β1 synergistically facilitate migration and chondrogenesis of synovium-derived stem cells through MAPK pathways.

Authors:  Yiming Wang; Jifei Chen; Wenshuai Fan; Jing Zhang; Bingxuan Hua; Bolin Sun; Liang Zhu; Xinhao Niu; Zuoqin Yan; Changan Guo
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

8.  Tgfbr1 haploinsufficiency is a potent modifier of colorectal cancer development.

Authors:  Qinghua Zeng; Sharbani Phukan; Yanfei Xu; Maureen Sadim; Diana S Rosman; Michael Pennison; Jie Liao; Guang-Yu Yang; Chiang-Ching Huang; Laura Valle; Antonio Di Cristofano; Albert de la Chapelle; Boris Pasche
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

9.  Malignancy in scleroderma patients from south west England: a population-based cohort study.

Authors:  Keith Siau; C J Laversuch; P Creamer; K P O'Rourke
Journal:  Rheumatol Int       Date:  2010-01-08       Impact factor: 2.631

10.  TGF-beta induces apoptosis in human B cells by transcriptional regulation of BIK and BCL-XL.

Authors:  L C Spender; D I O'Brien; D Simpson; D Dutt; C D Gregory; M J Allday; L J Clark; G J Inman
Journal:  Cell Death Differ       Date:  2009-01-09       Impact factor: 15.828
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.